To assess long-term outcomes of double internal stents (DIS) for the relief of external malignant ureteral obstruction (MUO). DIS (7 FR each; 12-month indwelling time) were inserted under general anesthesia in 62 consecutive patients (75 renal units) with MUO during 2007-2018.
To compare the efficacies of mirabegron 50 mg addition after alpha-adrenoreceptor blocker in terms of reducing storage symptoms in patients with BPH. Fifty-eight patients that had been taking alpha-adrenoreceptor blocker for more than 8 weeks, but had an OABSS of greater than 3 points, were initially enrolled.
Currently, no study has focused on the postoperative erectile function in patients with benign prostatic hyperplasia (BPH) by comparing Hiraoka’s transurethral detachment of prostate (TUDP) and transurethral resection of prostate (TURP).
This study aimed to assess the midterm outcomes and safety of prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH). A single-center, retrospective review of PAE performed for BPH was performed.
Prediction of prostate cancer in primary care is typically based upon serum total prostate-specific antigen (tPSA) and digital rectal examination results. However, these tests lack sensitivity and specificity, leading to over-diagnosis of disease and unnecessary, invasive biopsies.
(UroToday.com) As part of the “Game-Changing Session 1” plenary presentation at the 2020 European Association of Urology (EAU) Virtual Annual Meeting, Dr. Michael Hofman presented results of the proPSMA study which was recently published in the Lancet.1
(UroToday.com) As part of the “Game-Changing Session 1” plenary presentation at the 2020 European Association of Urology (EAU) Virtual Annual Meeting, Dr. Jens-Uwe Stolzenburg presented his abstract entitled “Continence Following Robot-Assisted (R-LRPE) and Conventional Laparoscopic Radical Prostatectomy (LRPE) – Results of a Prospective, Randomized, Multicenter, Patient Blinded Study”. While robotic-assisted radical prostatectomy has supplanted open and […]
(UroToday.com) Dr. Alison Birtle gave a talk on the ever-changing treatment paradigm of advanced prostate cancer (Figure 1). Metastatic castrate-resistant prostate cancer (mCRPC) is a lethal disease with huge heterogeneity. The same patient can have coexistence of androgen receptor-dependent and independent tumor cells. The sequencing of therapies is even more important given the use of […]
(UroToday.com) In this discussion, Dr. Perner elaborated on the various molecular subtypes of prostate cancer. It has been shown that there are potentially actionable mutations in 25% of cases in the PIK3CA/MAPK signaling pathway and almost 20% alteration in DNA damage repair genes (Figure 1).
(UroToday.com) In this debate, a clinical case of a 65-year-old gentleman who was diagnosed with prostate cancer Gleason grade group 2 on biopsy was presented by Giorgio Gandaglia, MD. The patient underwent robotic-assisted radical prostatectomy, demonstrating pT3a, Gleason grade group 4 with negative margins on final pathology, with no lymph node dissection performed. The first postoperative prostate-specific […]
